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Summary 
Background: The results of the EINSTEIN-DVT/PE and AMPLIFY trials, which 
compared rivaroxaban and apixaban with conventional anticoagulation therapy for 
acute venous thromboembolism (VTE), respectively, are often compared. However, 
the trials differed in duration of therapy (3-12 and 6 months, respectively) and in 
patient selection (few exclusion criteria and more stringent exclusion criteria, 
respectively). 
Methods: To determine the effect of these methodological differences on outcomes, 
the patients enrolled in EINSTEIN-DVT/PE were divided into 2 cohorts; the 5253 
patients that matched the exclusion criteria for AMPLIFY and were treated for at least 
6 months (cohort 1) and the 2368 patients who would have been ineligible for 
AMPLIFY (cohort 2). 
Results: Compared with patients in cohort 2, those in cohort 1 were older and more 
often male and there were more with unprovoked VTE, prior VTE, cancer and known 
thrombophilia. In cohort 1, rivaroxaban would have significantly reduced recurrent 
VTE (relative risk [RR], 0.64; 95% confidence interval [CI], 0.43-0.95) and major 
bleeding (RR, 0.50; 95% CI, 0.30-0.82) compared with conventional therapy, 
whereas the two treatments would have had similar effects on recurrent VTE (RR, 
1.08; 95% CI, 0.65-1.79) and major bleeding (RR, 1.03; 95% CI, 0.48-2.18) in cohort 
2. 
Conclusions: This analysis illustrates the influence of patient selection and 
treatments duration on outcome results and highlights the limitations of cross-trial 
comparisons. 
 
Funding: Drs Lensing, Pap, and Trajonovic are paid employees of Bayer Healthcare 
and devoted salaried time to this work; the other authors were unsupported. 
Previous Presentation: This study was presented at the ISTH SSC 2016, 62nd 
Annual Meeting of the International Society on Thrombosis and Haemostasis; May, 
2016, Montpellier, France. 
Key words: anticoagulation, rivaroxaban, apixaban, venous thromboembolism. 
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Introduction 
Recent randomised active-controlled trials that included over 27,000 patients have 
established the direct oral anticoagulants (DOACs) as efficacious and safe treatment 
options for patients with acute symptomatic venous thromboembolism (VTE).[1-6] 
With fixed dosing and no need for routine coagulation monitoring, the DOACs are 
convenient to administer and they are rapidly replacing vitamin K antagonists (VKA) 
for initial, long-term and extended VTE treatment. 
Selection among the DOACs is challenging because they have not been compared in 
a head-to-head manner. Although the respective DOAC trials shared many 
similarities with regard to primary objective, comparator therapy, outcome definitions 
and central event adjudication, a number of differences existed in trial design and 
patient selection criteria. However, the impact of these trial differences on study 
outcomes is currently unknown. This gap in knowledge may have clinical 
consequences because indirect comparisons between DOACs have been conducted 
using meta-analytic or network meta-analytic techniques,[7-12] but the results of 
these analyses may be misleading because of differences in study design and patient 
selection criteria.[13-15] This creates challenges for physicians and other health care 
professionals as they seek to understand, interpret, and apply the results of the 
studies in their clinical practices.[16, 17] 
To evaluate the impact of differences in trial design and inclusion and exclusion 
criteria on outcomes in DOAC VTE treatment trials we applied the main design 
features of the apixaban study (AMPLIFY) to patient cohorts from the studies with 
rivaroxaban (EINSTEIN DVT and EINSTEIN PE, which were performed as separate 
studies with a pre-specified pooled analysis) 1-3,18. In both study programs initial 
heparin therapy was not required for patients receiving DOAC treatment and many 
patients had no heparin or received only a single heparin dose prior to randomization. 
More specifically, EINSTEIN DVT/PE and AMPLIFY shared the following features:  
All three studies used the same blinded independent adjudication committee which 
employed identical diagnostic criteria for confirmation of the index and recurrent 
symptomatic VTE events and for the evaluation of suspected bleeding events. In all 
three studies, (a) recurrent VTE was evaluated for the intention-to-treat population, 
(b) bleeding events were evaluated for the on-treatment (+2 days) population, and (c) 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
4 
 
haemoglobin, platelet count, alanine aminotransferase (ALT), and total bilirubin were 
measured at baseline. 
In EINSTEIN-DVT/PE, patients randomised to the rivaroxaban arm were given the 
drug at a dose of 15 mg twice-daily for 21 days and the dose was then reduced to 20 
mg once-daily thereafter. In AMPLIFY, patients randomised to receive apixaban were 
given the drug at a dose of 10 mg twice-daily for 7 days followed by 5 mg twice-daily 
thereafter. There was no downward adjustment of the doses of rivaroxaban or 
apixaban on the basis of clinical criteria such as older age, low body weight or 
moderate renal impairment. Heparin bridging was not given and the pre-
randomization use of heparin was restricted to a limited number of doses. 
Comparator treatment in the trials consisted of enoxaparin (1 mg/kg body weight 
twice-daily) for a minimum of 5 days overlapping with a VKA (warfarin or 
acenocoumarol in EINSTEIN-DVT/PE and warfarin in AMPLIFY). Enoxaparin was 
stopped when the INR was 2 or higher and VKA was dose adjusted to maintain the 
INR between 2 and 3. 
Patients were ineligible if they were allergic to the drugs used for comparator 
treatment, had limited life expectancy, had severe renal impairment, had bacterial 
endocarditis, used strong inhibitors of CYP3A4, or had received an investigational 
agent within the past 30 days prior to the first dose of study treatment. In addition, the 
studies excluded women who were pregnant or breast feeding and women of 
childbearing potential not taking adequate measures to prevent pregnancy. 
 
On the other hand, EINSTEIN DVT/PE and AMPLIFY differed in a number design 
features.   
The EINSTEIN-DVT/PE trials used a PROBE design (i.e., prospective, randomised, 
open, blinded endpoint evaluation), whereas the AMPLIFY trial was conducted in a 
double-blind, double-dummy manner and a point-of-care device was used to provide 
real or sham international normalised ratio (INR) values. The EINSTEIN-DVT/PE 
studies were conducted using a single protocol but applying separate randomization 
for patients with deep vein thrombosis (DVT) and for those with pulmonary embolism 
(PE) with or without accompanying DVT. In contrast, the AMPLIFY trial included 
patients with acute symptomatic VTE and stratified them according to presentation as 
DVT or PE. 
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Treatment duration- In EINSTEIN-DVT/PE, patients were eligible if they required 
anticoagulant therapy for a period of at least 3, 6 or 12 months. In AMPLIFY, patients 
were only eligible if they required anticoagulant therapy for at least 6 months.  
VTE provoked by a transient risk factor- In EINSTEIN-DVT/PE, patients with 
provoked or unprovoked VTE could be included, whereas in AMPLIFY patients were 
ineligible if they had VTE provoked by a transient risk factor 
High risk for bleeding- The exclusion criteria related to a potential for increased 
bleeding were more extensive for AMPLIFY than for EINSTEIN-DVT/PE. Although 
patients with overt bleeding and those considered at high risk of bleeding were 
excluded from all studies, the AMPLIFY trial also excluded those with  haemoglobin < 
9 g/dL, ALT >2 times upper limit of normal (ULN) rather than >3 times ULN as in 
EINSTEIN-DVT/PE, total bilirubin >1.5 times ULN, requirement for ASA >165 
mg/day, requirement for dual antiplatelet therapy, platelet count <100 x 109/L, recent 
(<6 months) intracranial bleeding, intraocular bleeding, gastrointestinal bleeding, 
endoscopically verified ulcer disease, recent (<1 week) ischemic stroke or 
neurosurgery, or recent (< 2 months) head trauma, other major trauma, or major 
surgery. In addition, patients were excluded from AMPLIFY if they had an intracranial 
neoplasm, arteriovenous malformation or aneurysm.  
Table 1 lists the relevant differences in treatment duration and exclusion criteria in 
the EINSTEIN-DVT/PE and AMPLIFY trials and indicates the adaptation of the 
EINSTEIN-DVT/PE cohort to reflect the AMPLIFY criteria. 
 
Taken together, the EINSTEIN-DVT/PE and AMPLIFY trials especially differed in the 
duration of therapy and in patient selection. In the EINSTEIN-DVT/PE trials, there 
were few exclusion criteria and anticoagulation therapy could be given for 3, 6 or 12 
months at the discretion of the treating physician.[2, 3, 18] In contrast, the exclusion 
criteria were more stringent for the AMPLIFY study, and all patients were treated for 
6 months.[1]  
 To evaluate the impact of these trial design differences on treatment outcomes, we 
compared rates of recurrent VTE and major bleeding for EINSTEIN-DVT/PE patients 
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who received at least 6 months of anticoagulant therapy in those who met or did not 
meet the eligibility criteria employed in the AMPLIFY trial. 
 
Methods 
Detailed descriptions of the study design of the EINSTEIN-DVT/PE and AMPLIFY trials have 
been published.[1-3] and were registered at ClinicalTrials.gov, numbers 
NCT00440193, NCT00439777, and NCT00643201.  
 
 
Differences in study design of the EINSTEIN-DVT/PE and AMPLIFY trials 
The steps taken to adjust the data from EINSTEIN-DVT/PE to mimic the AMPLIFY 
design are listed in Table 1, which includes the number of patients involved. First, 
patients from EINSTEIN-DVT/PE with an intended treatment duration of 3 months 
were excluded because such patients were not enrolled in AMPLIFY. Second, the 
evaluation was truncated at 6 months in EINSTEIN-DVT/PE patients whose intended 
treatment duration was 12 months. Third, the exclusion criteria used in AMPLIFY 
were applied to identify a similar cohort of patients enrolled in the EINSTEIN-DVT/PE 
trials (EINSTEIN cohort 1), and a cohort who would not have been eligible for 
AMPLIFY (EINSTEIN cohort 2). Separate analyses were performed for both cohorts. 
 
Statistical Analyses 
For comparison of demographic and clinical characteristics of patients in EINSTEIN-
DVT/PE cohort 1 and AMPLIFY, standardised difference scores were calculated.[19] 
For better comparison of outcome results, the EINSTEIN-DVT/PE results, which were 
originally expressed in hazard ratios, were presented as relative risk (RR). The 95% 
confidence intervals (CI) were calculated using the Mantel-Haenszel method and 
stratified according to the qualifying diagnosis (DVT or PE±DVT) and intended 
treatment duration (6 or 12 months). The times during which the INR was below, 
within or above the therapeutic range were calculated for each patient from the time 
of discontinuation of heparin until the end of treatment (including interruptions) and 
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were compared using multivariate ANOVA. Adverse events resulting in permanent 
discontinuation of study drug in the two EINSTEIN cohorts were compared using the 
chi-square test.  
Outcome Measures 
Efficacy and safety outcomes were defined identically in EINSTEIN-DVT/PE and 
AMPLIFY. The primary efficacy outcome was the adjudicated composite of recurrent 
symptomatic VTE (i.e. fatal or nonfatal PE and DVT). Major bleeding was defined as 
overt bleeding that was associated with a decrease in the hemoglobin level of 2 g/dL 
or more, required the transfusion of 2 or more units of blood, occurred in a critical 
site, or contributed to death.  
 
Role of the funding source 
Bayer HealthCare Pharmaceuticals and Janssen Research and Development, the 
funders of the EINSTEIN-DVT and EINSTEIN-PE studies, gathered, maintained, and 
extracted data. The authors had responsibility for interpreting the data and writing the 
article. JBW, AWAL, MPH, and JIW had access to the raw data. The corresponding 
author had full access to all of the data and the final responsibility to submit for 
publication. 
 
Results 
A total of 660 (8.0%) of the 8282 EINSTEIN-DVT/PE patients had an intended 
treatment of 3 months and were excluded from further analyses. Next, study duration 
was truncated at 6 months for 2681 patients who had a treatment duration > 6 
months in EINSTEIN DVT/PE. As indicated in figure 1, application of the AMPLIFY 
eligibility criteria to the 7621 EINSTEIN-DVT/PE patients with an intended treatment 
duration of 6 or 12 months resulted in 1) a cohort of 5253 EINSTEIN-DVT/PE 
patients whose inclusion criteria matched those of patients enrolled in AMPLIFY 
(EINSTEIN-DVT/PE cohort 1) and 2) a cohort of 2368 EINSTEIN-DVT/PE patients 
who would not been eligible for enrollment in AMPLIFY (EINSTEIN-DVT/PE cohort 
2), 
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Table 2 specifies the demographic and clinical characteristics of the patients included 
in the two EINSTEIN-DVT/PE cohorts and in AMPLIFY. Compared with patients in 
EINSTEIN-DVT/PE cohort 2, those in cohort 1 were older and more often male, and 
a greater proportion had unprovoked VTE, a history of prior VTE, or known 
thrombophilia. Compared with patients in AMPLIFY, patients in cohort 1 of 
EINSTEIN-DVT/PE were slightly older and more had PE, prior history of VTE, known 
thrombophilia, or active cancer. Overall, time spent with the INR below, within, and 
above the therapeutic range of 2.0 to 3.0 was similar for patients in cohort 1, cohort 2 
and AMPLIFY (Table 2). Adverse events leading to permanent discontinuation of 
study drug occurred with similar frequency in both EINSTEIN-DVT/PE cohorts and 
AMPLIFY. 
Clinical Outcomes 
Recurrent VTE occurred in 99 (1.9%) of 5253 patients in cohort 1 and 58 (2.5%) of 
2368 patients in cohort 2 (RR, 0.76; 95% CI, 0.55-1.06), whereas major bleeding 
occurred in 67 (1.3%) of 5233 and 27 (1.1%) of 2358 patients in cohorts 1 and 2, 
respectively (RR, 1.19; 95% CI, 0.75-1.90; Table 3).  
In EINSTEIN-DVT/PE cohort 1, the rate of recurrent VTE was significantly lower with 
rivaroxaban than with enoxaparin/VKA (1.5% and 2.3%, respectively; RR, 0.64; 95% 
CI, 0.43-0.95; p=0.027). In contrast, the rates of recurrent VTE with rivaroxaban and 
enoxaparin/VKA were similar in cohort 2 (2.6% and 2.3%, respectively; RR, 1.08; 
95% CI, 0.65-1.79; p=0.77; Table 3 and Figure 2). Likewise, the rate of major 
bleeding was significantly lower with rivaroxaban than with enoxaparin/VKA in 
EINSTEIN-DVT/PE cohort 1 (0.8% and 1.7%, respectively; RR, 0.50; 95% CI, 0.30-
0.82; p=0.0068) but not in cohort 2 (1.2% and 1.1%, respectively; RR, 1.03; 95% CI, 
0.48-2.18; p=0.95; Figure 3). 
The first recurrent VTE or major bleeding event in the intention-to-treat population 
occurred significantly less frequently with rivaroxaban than with enoxaparin/VKA in 
cohort 1 (2.4% and 4.0%, respectively; RR, 0.60; 95% CI, 0.44-0.81; p=0.0011) 
indicating a superior net clinical benefit with rivaroxaban. In contrast, the frequency of 
the first recurrent VTE or major bleeding event was similar with rivaroxaban and 
enoxaparin/VKA in cohort 2 (3.9% and 3.6%, respectively; RR, 1.06; 95% CI, 0.70-
1.59; p=0.79).  
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Discussion 
Our results indicate that had the AMPLIFY eligibility criteria been applied to patients 
enrolled in the EINSTEIN-DVT/PE trials, 31.1% of the patients would have been 
ineligible. Although ineligible for AMPLIFY, these patients were included in EINSTEIN 
DVT/PE and form cohort 2. Compared with patients in cohort 1 who met the 
AMPLIFY eligibility criteria, those in cohort 2 who did not meet these criteria had an 
almost 1.5- to 2-fold higher risk of recurrent VTE and major bleeding during 
rivaroxaban therapy. This difference shows that treatment duration and modest 
variations in eligibility criteria can impact on outcome results, thereby highlighting the 
limitations of cross study comparisons.  
Casual inspection of the results of the EINSTEIN-DVT/PE and AMPLIFY trials 
suggests that apixaban and rivaroxaban are similarly efficacious because the rates of 
recurrent VTE are 2.3% vs. 2.1%, respectively, but that apixaban is associated with a 
lower absolute rate of major bleeding than rivaroxaban (0.6% vs. 1.0%, respectively) 
and a greater risk reduction in major bleeding compared with enoxaparin/VKA (RR, 
0.31 vs. 0.54, respectively). However, the results of the current analysis suggest that 
had the AMPLIFY treatment duration and exclusion criteria been applied in 
EINSTEIN-DVT/PE, rivaroxaban would have significantly reduced the risk of 
recurrent VTE compared with enoxaparin/VKA (RR, 0.64; 95% CI, 0.43-0.95) and 
would have been associated with an even greater reduction in the risk of major 
bleeding (RR, 0.50; 95% CI, 0.30-0.82). Of note, compared with the AMPLIFY 
population, patients in EINSTEIN-DVT/PE cohort 1 still had a somewhat higher risk 
profile, since they more often had PE, prior VTE, known thrombophilia or active 
cancer, which has been shown to be a relevant risk factor for both VTE recurrence 
and bleeding during anticoagulation. [20, 21]. Therefore, our findings may even 
underestimate the impact of patient selection on outcomes in AMPLIFY. 
It may be argued that the majority of patients in EINSTEIN DVT/PE cohort 2 had 
provoked VTE, for which current guidelines recommend a treatment duration of 3 
months, whereas these patients were selected to receive at least 6 months of 
anticoagulant therapy by their attending physicians. However, the risk of VTE 
recurrence after provoked VTE has been shown to range between 7-10% in the first 
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two years after index event. [22, 23]. Furthermore, during anticoagulation we observed 
a numerically higher rate of recurrent VTE in patients with provoked VTE compared 
to those with unprovoked VTE, which likely reflects the co-morbidity profile of patients 
with provoked VTE chosen to continue anticoagulation beyond 3 months.  In addition, 
in the benefit-risk evaluation of the EINSTEIN Extension study [24], patients with 
provoked VTE had a similar recurrent VTE risk as compared to patients with 
unprovoked VTE. The number needed to treat with rivaroxaban to prevent 1 recurrent 
VTE was 16 for patients with unprovoked VTE and 14 for patients with provoked 
VTE, respectively. Finally, while VTE provoked by surgical triggers indeed has a very 
low risk of recurrence, VTE events provoked by “soft triggers” have been shown to 
have a considerably high VTE recurrence risk [25] that may, together with other 
factors such as family history, clot burden of index event, d-dimer values or patients` 
preferences, guide the decision to prolong anticoagulation beyond 3 months.   
According to the outcome event rates of EINSTEIN cohort 2, the EINSTEIN-DVT/PE 
studies included a large proportion of patients who appear to have both a higher risk 
of recurrent VTE and a higher risk of major bleeding than those that met the inclusion 
and exclusion criteria used in AMPLIFY. Although the use of more stringent exclusion 
criteria may help to optimize internal validity, increase study feasibility, reduce cost, 
and alleviate ethical concerns by excluding patients who might be harmed by study 
participation, limiting enrollment may distort demographic characteristics (see Table 
2) and yield lower rates of study outcomes (see Table 3). Therefore, the use of more 
stringent exclusion criteria has the potential to limit the generalizability (the so-called 
external validity) of the results to real-world practice. Consequently, enrollment of the 
broadest possible patient population is important to avoid such bias,[17] and the 
product label needs to reflect the applied exclusion criteria used in the various phase 
3 trials.  
This post-hoc comparison of the EINSTEIN-DVT/PE and AMPLIFY studies was 
performed on prospectively collected data and was enabled by the similarities in 
study design, including documentation of the inception cohorts, use of the same 
comparator (enoxaparin/VKA), identical outcomes and central assessment of 
outcomes by the same blinded adjudication committee. Nonetheless, our study has 
limitations. First, because this is a post-hoc analysis, we cannot exclude the 
possibility that different results may be obtained if the EINSTEIN-DVT/PE studies had 
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been performed prospectively using the AMPLIFY trial design. Second, splitting the 
EINSTEIN-DVT/PE population into smaller subgroups reduces the statistical power of 
our analysis. However, because EINSTEIN-DVT/PE included over 8000 patients, 
even after excluding patients in cohort 2, cohort 1 still had a similar number of 
patients as was included in the AMPLIFY trial. Finally, because we did not have 
access to the raw data, only aggregate results from the AMPLIFY study could be 
used in this analysis. Despite these limitations, this post-hoc analysis suggests that 
had the AMPLIFY exclusion criteria and treatment duration been applied in the 
EINSTEIN-DVT/PE trials, rivaroxaban would have been superior to enoxaparin/VKA 
in both efficacy and safety. 
This study suggests that modest differences in study design can have a major impact 
on study outcomes. In the absence of head-to-head trials comparing one agent with 
another, this fact needs to be considered when making treatment decisions on the 
basis of cross study comparisons. Furthermore, our findings suggest that indirect 
comparisons such as network-analyses may be misleading, if they do not fully adjust 
for trial differences. 
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Table 1. Comparison of treatment duration and 
exclusion criteria in AMPLIFY and EINSTEIN-
DVT/PE and adjustment of EINSTEIN-DVT/PE data 
to reflect the AMPLIFY dataAMPLIFY 
EINSTEIN-DVT/PE EINSTEIN-DVT/PE adaptation to 
reflect AMPLIFY 
No of 
patients 
affected 
Treatment Duration   
Planned treatment duration of at least 6 months Planned treatment duration 
of 3, 6, or 12 months 
Patients in the 3-month intended 
treatment duration group excluded 
660 
Total treatment duration of 6 months Up to 12 months  Analysis censored at 6 months for 
patients with intended 12-months 
treatment duration 
2681 
Exclusion criteria 
 General 
Patients with VTE provoked by a transient risk factor Provoked VTE included Patients with VTE provoked by a 
transient risk factor excluded 
1817 
 
 Risk factors for bleeding at baseline   1518 
Haemoglobin < 9 g/dL No limitation for haemoglobin Patients with Hb < 9 g/dL excluded 84 
ALT > 2 times ULN  ALT ≥ 3 times ULN Patients with ALT > 2 times ULN 
excluded 
145 
Total bilirubin >1.5 times ULN No limitation for bilirubin Patients with total bilirubin > 1.5 times 
ULN excluded 
63 
Requiring ASA >165 mg/day ASA was discouraged Patients using ASA > 165 mg (7-day 
post randomization window) excluded 
18 
Requiring dual antiplatelet therapy No limitation for dual 
antiplatelet therapy 
Patients using dual antiplatelet therapy 
(7-day post randomization window) 
excluded 
16 
Platelet count < 100 x 10
9
/L No limitation for platelet 
count 
Patients with a platelet count < 100 x 
10
9
/L
 
excluded 
73 
Heparin-induced thrombocytopenia (HIT) Contraindication for use of 
heparin 
Patients with (history of) HIT excluded 0 
Recent bleeding (< 6 months): intracranial, 
intraocular, gastrointestinal, or endoscopically 
verified ulcer disease 
Patients at high risk of 
bleeding excluded 
Patients with intracranial, intraocular, 
gastrointestinal bleeding and those 
with endoscopically verified ulcer 
disease (< 6 months) excluded 
21 
Recent (< 1 week): ischemic stroke or neurosurgery Patients at high risk of 
bleeding or recent surgery or 
trauma excluded 
 
Patients with a stroke or neurosurgery 
(<1 week) excluded 
5 
At time of randomization: gross hematuria, evidence Patients at high risk of Patients excluded, if at time of 38 
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of poor healing of a major wound, major trauma or 
overt major bleeding, planned major surgery, 
intracranial neoplasm, arteriovenous malformation or 
aneurysm, documented hemorrhagic tendencies, or- 
blood dyscrasias 
bleeding excluded randomization: gross hematuria, 
evidence of poor healing of a major 
wound, major trauma or overt major 
bleeding, planned major surgery, 
intracranial neoplasm, arteriovenous 
malformation or aneurysm, 
documented hemorrhagic tendencies, 
or blood dyscrasias 
Recent (< 2 months): head trauma, other major 
trauma, or major surgery 
Patients at high risk of 
bleeding or those with recent 
surgery or trauma excluded 
Patients with (< 2 months: head 
trauma, other major trauma, or major 
surgery excluded 
1167 
 Other    
Creatinine clearance < 25 mL/min < 30 mL/min No correction  
Life expectancy < 6 months <3 months No correction  
Active and clinically significant liver disease Identical No correction  
    
2 doses of fondaparinux or a once-daily LMWH, or > 
3 doses of a twice-daily LMWH, or continuous 
infusion of UFH for > 36 hrs; and/or > 2 doses of 
VKA 
Identical No correction 
 
 
Receiving concurrent investigational agents or has 
received an investigational agent within the past 30 
days prior to the first dose of study treatment 
Identical No correction  
Thrombectomy, insertion of a cava filter, or use of a 
fibrinolytic agent to treat the current episode of DVT 
and/or PE 
Identical No corrections  
Subjects with cancer who will be treated for 6 months 
or more with LMWH therapy 
Patients with cancer 
requiring long-term LMWH 
therapy were ineligible 
No correction  
Bacterial endocarditis Identical No correction  
- Prisoners/subjects who are involuntarily 
incarcerated 
- Subjects who are compulsorily detained for 
treatment of either a psychiatric or physical (eg, 
infectious disease) illness 
- Any condition, which in the opinion of the 
investigator, would put the subject at an 
unacceptable risk from participating in the study 
Not specifically defined as 
exclusion criteria but these 
are general ineligibility 
criteria 
No correction  
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- Any other medical, social, logistical, or 
psychological reason, which in the opinion of the 
investigator, would preclude compliance with, or 
successful completion of, the study protocol. 
Women who were pregnant or breast feeding or 
women of childbearing potential not taking adequate 
measures to prevent pregnancy. 
Identical No correction  
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Table 2. Demographic and clinical characteristics of EINSTEIN-DVT/PE patients who were and were not potentially eligible for the AMPLIFY study. 
 Cohort 1: EINSTEIN-DVT/PE 
patients eligible for AMPLIFY; 
n=5253 
Cohort 2: EINSTEIN-DVT/PE 
patients ineligible for 
AMPLIFY; n=2368 
P-value 
cohort 1 vs cohort 
2 
AMPLIFY  
N=5395 
Age — yr  59.4±16.0 53.0±17.6 P<0.0001 57.0±16.0 
Male sex — no. (%) 3122 (59.4) 1060 (44.8) P<0.0001 3167 (58.7)  
Weight  
 Mean — kg  
 
83.5±18.4 
 
81.8±19.5 
 
P=0.0002 
 
84.6±19.8 
Weight  
 Distribution; — no. (%)  
  ≤60 kg 
  >60 to < 100 kg 
  > 100 kg 
  Data missing 
 
 
467 (8.9) 
3977 (75.8) 
803 (15.3) 
6 (0.1) 
 
 
304 (12.9) 
1736 (73.4) 
324 (13.7) 
4 (0.2) 
 
P<0.0001 
 
 
476(8.8) 
3868 (71.7) 
1040 (19.3) 
11 (0.2) 
Qualifying diagnosis — no. (%) 
 DVT 
 PE 
 PE with DVT 
 Could not be evaluated  
 
2098 (39.9) 
2281 (43.4) 
821 (15.6) 
53 (1.0) 
 
888 (37.5) 
1112 (47.0) 
349 (14.7) 
19 (0.8) 
P=0.034  
3532 (65.5) 
1359 (25.2) 
477 (8.8) 
27 (0.5) 
Time from onset of symptoms to randomization — days  
 Median 
 Interquartile range 
 
5.0 
(2.0-10.0) 
 
4.0 
(2.0-8.0) 
P<0.0001  
5.0 
(3.0-9.0) 
Clinical presentation of VTE — no. (%) 
 Unprovoked 
 Provoked 
 Not reported 
 
4797 (90.3) 
456 (8.7) 
- 
 
262 (11.1) 
2106 (88.9) 
- 
P<0.0001  
4845 (89.8) 
544 (10.1) 
6 (0.1) 
Risk factors for recurrent VTE — no. (%) 
 Previous VTE 
 Known thrombophilia 
 Active cancer 
 
1350 (25.7) 
433 (8.2) 
291 (5.5) 
 
229 (9.7) 
41 (1.7) 
111 (4.7) 
 
P<0.0001 
P<0.0001 
P<0.034 
 
872 (16.2) 
133 (2.4) 
143 (2.7) 
Treatment with LMWH, heparin, or fondaparinux before 
randomization — no. (%) 
 None 
 ≤12 hr 
 >12 to 24 hr 
 >24 to 48 hr 
 >48 hr 
 Data missing 
 
 
766 (14.6) 
460 (8.8) 
2697 (51.3) 
1263 (24.0) 
67 (1.3) 
- 
 
 
373 (15.8) 
214 (9.0) 
1135 (47.9) 
613 (25.9) 
33 (1.4) 
- 
P=0.10  
 
739 (13.7) 
712 (13.2) 
2242 (41.6) 
1642 (30.4) 
48 (0.9) 
12 (0.2) 
Time spent in an INR interval of 
< 2.0 
2.0 – 3.0 
> 3.0 
 
21.0%  
62.7%  
16.3%  
 
23.5%  
60.9% 
15.6 
P=0.0053 
 
 
23% 
61% 
16% 
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Adverse events resulting in permanent discontinuation 
of study drug (DOAC vs enoxaparin/VKA 
148 (5.7%) vs. 113 (4.3%) 48 (4.0%) vs. 53 (4.6%) P=0.20* 6.1% vs 7.4% 
Continuous variables are presented as means ± standard deviation. Percentages may not total 100 because of rounding. DVT denotes deep vein thrombosis, PE 
pulmonary embolism, VTE venous thromboembolism, INR international normalised ratio and LMWH low-molecular-weight heparin. *P-value calculated for all 
adverse events in cohort 1 versus all adverse events in cohort 2. 
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Table 3. Clinical outcomes in EINSTEIN-DVT/PE (original), EINSTEIN cohorts 1 and 2 and AMPLIFY 
 Einstein-DVT/PE 
N=8281 (ITT) 
Cohort 1: EINSTEIN-DVT/PE patients 
eligible for AMPLIFY; n=5253 
Cohort 2: EINSTEIN-DVT/PE patients 
ineligible for AMPLIFY; n=2368 
AMPLIFY 
n=5395 
 n (%) RR (95% CI) n (%)  RR (95% CI) n (%)  RR (95% CI) n (%)  RR (95% CI) 
Recurrent 
VTE 
DOAC vs 
LMWH/VKA 
86 (2.1%) vs  
95 (2.3%) 
0.90 (0.67-1.20) 38 (1.5%) vs 
61 (2.3%) 
0.64 (0.43-0.95; 
p=0.027) 
31 (2.6%) vs 
27 (2.3%) 
1.08 (0.65-1.79; 
p=0.77) 
59 (2.3%) vs 
71 (2.7%) 0.84 (0.60-1.18) 
Major 
bleeding 
DOAC vs 
LMWH/VKA 
40 (1.0%) vs  
72 (1.7%) 
0.55 (0.38-0.81) 22 (0.8%) vs 
45 (1.7%) 
0.50 (0.30-0.82; 
p=0.0068) 
14 (1.2%) vs 
13 (1.1%) 
1.03 (0.48-2.18; 
p=0.95) 
15 (0.6%) vs 
49 (1.8%) 0.31 (0.17-0.55) 
RR denotes Relative Risk, DOAC non-vitamin K antagonist oral anticoagulants, LMWH low-molecular-weight heparin and VKA vitamin K antagonists 
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Table 4. Recurrent VTE and major bleeding according to risk factor profile in patients included in EINSTEIN but excluded in AMPLIFY (Cohort  2) 
 Risk factor profile Rivaroxaban Enoxaparin/VKA Hazard ratio (95% CI) Pinteraction 
Recurrent VTE      
 Provoked VTE transient risk factor  22/ 917 (2.4%) 21/900 (2.3%) 1.00 (0.55-1.82) 0.72 
 Provoked VTE permanent risk factor 3/61 (4.9%) 3/50 (6.0%) 0.71 (0.14-3.54)  
 Unprovoked VTE 6/235 (2.6%) 3/205 (1.5%) 1.58 (0.39-6.36)  
Major bleeding      
 Provoked VTE  transient risk factor 11/ 913 (1.2%) 9/897 (1.0%) 1.19 (0.49-2.88) 0.70 
 Provoked VTE permanent risk factor 3/61 (4.9%) 2/50 (4.0%) 1.19 (0.19-7.39)  
 Unprovoked VTE 1/234 (0.4%) 2/203 (1.0%) 0.34 (0.03-3.70)  
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Table 5. Major bleeding in patients included in EINSTEIN (Cohort 2) who met none, one or more than one bleeding exclusion criterion of the 
AMPLIFY study. 
Bleeding 
exclusion 
criteria met 
Cohort 2 Pinteraction Hazard ratio (95% 
CI) versus none 
Ptrend 
none 6/838 (0.7%) 0.92  0.22 
1 20/1403 (1.4%)  2.16 (0.87-5.39)  
>1 2/107 (1.9%)  2.71 (0.54-13.49)  
missing 0/8    
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